Press Release - January 06, 2021
Advancing peptides for the treatment of rare endocrine and metabolic disorders
We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.
PROGRAMS
AZP-3601
Our lead clinical candidate is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.
AZP-3601 (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.
AZP-3404
AZP-3404 is a first-in-class therapeutic peptide that may restore fat and glucose metabolism in the body.
AZP-38XX
We are testing a series of novel, highly potent, small peptide antagonists of the growth hormone (GH) receptor to select a lead development candidate for treatment of acromegaly.
HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.
LEADERSHIP
Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.
Press Releases & Recent News
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Download a PDF copy of this …
Amolyt Pharma Announces Research Collaboration with PeptiDream
Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream …